LexDanaLexDanabeta
Inventor

Napoleone Ferrara

Inventor
San Francisco, CA, US

Overview

100→
Patents
1994–2016
Patent span
Chemistry
Primary field (CPC C)

Patents· 100 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides26%
A61KPreparations for medical, dental or toiletry purposes21%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations13%
C12NMicroorganisms or enzymes11%
G01NInvestigating or analysing materials by determining their chemical or physical properties9%
C07HSugars8%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture4%
Y02PClimate change mitigation technologies in the production or processing of goods3%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
9,273,113'Methods of inhibiting vascular endothelial growth factor activity'20169,266,948'Anti-Bv8 antibodies and uses thereof'20168,858,936'Compositions with hematopoietic and immune activity'20148,771,685'Anti-BV8 antibodies and uses thereof'20148,604,185'Inhibitors of angiopoietin-like 4 protein, combinations, and their use'20138,557,238'EG-VEGF nucleic acids and polypeptides and methods of use'20138,541,376'Composition comprising and method of using angiopoietin-like protein 3 ANGPTL3'20138,287,873'Vascular endothelial cell growth factor antagonists and uses thereof'20128,273,353'Inhibitors of vascular endothelial growth factor activity'20128,268,313'Methods for using inhibitors of vascular endothelial growth factor activity'20128,268,591'Compositions and methods for producing inhibitors of vascular endothelial growth factor activity'20128,257,702'Compositions with hematopoietic and immune activity'20128,110,720'Transgenic mice expressing humanized VEGF'20128,012,482'Humanized anti-TGF-beta antibodies'20118,007,799'Vascular endothelial cell growth factor antagonists and uses thereof'20117,998,931'Vascular endothelial cell growth factor antagonists and uses thereof'20117,960,531'EG-VEGF nucleic acids and polypeptides and methods of use'20117,811,984'BV8 nucleic acids and polypeptides with mitogenic activity'20107,771,721'Methods for using chimeric vascular endothelial growth factor receptor proteins'20107,740,846'Inhibitors of angiopoietin-like 4 protein, combinations, and their use'20107,736,645'EG-VEGF nucleic acids and polypeptides and methods of use'20107,727,536'EG-VEGF nucleic acids and polypeptides and methods of use'20107,709,455'Compositions and methods for liver growth and liver protection'20107,700,571'Compositions and methods for liver growth and liver protection'20107,632,810'Compositions with hematopoietic and immune activity'20097,619,062'PRO214 polypeptides'20097,575,879'Polypeptides homologous to VEGF and BMP1'20097,557,192'Anti-PRO335 antibodies'20097,527,791'Humanized anti-TGF-beta antibodies'20097,494,977'Polypeptides homologous to VEGF and BMP1'20097,470,771'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20087,449,551'PRO211 polypeptides'20087,446,168'EG-VEGF nucleic acids and polypeptides and methods of use'20087,427,596'Variants of vascular endothelial cell growth factor, their uses, and processes for their production'20087,390,879'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20087,378,507'PRO217 polypeptides'20087,371,377'Antibodies to polypeptides homologous to VEGF and BMP1'20087,355,002'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20087,317,092'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20087,307,152'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20077,300,791'Production of vascular endothelial cell growth factor and DNA encoding same'20077,267,819'Composition comprising and method of using angiopoietin-like protein 3 Angptl3'20077,264,801'EG-VEGF nucleic acids and polypeptides and method of use'20077,223,586'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20077,208,308'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20077,196,165'PRO363 polypeptides'20077,189,529'PRO792 nucleic acids'20077,169,906'PRO211 polypeptides'20077,157,267'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20077,151,160'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20067,147,853'Anti-pro211 polypeptide antibodies'20067,135,334'PRO20044 nucleic acids'20067,122,631'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20067,101,984'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20067,098,312'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20067,094,567'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20067,074,592'Secreted and transmembrane polypeptides nucleic acid encoding'20067,070,955'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20067,060,278'Bv8 nucleic acids and polypeptides with mitogenic activity'20067,056,736'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20067,041,805'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20067,033,786'Pro1340 nucleic acids'20067,034,123'Anti-PRO1347 antibodies'20067,026,448'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20067,026,449'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20067,018,837'Nucleic acids encoding secreted polypeptides that stimulate release of proteoglycans from cartilage'20067,005,505'Variants of vascular endothelial cell growth factor'20066,974,689'Nucleic acid encoding PRO211 polypeptides'20056,969,758'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20056,965,015'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20056,951,921'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20056,946,263'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20056,946,262'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20056,936,436'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20056,936,254'Method of inducing fetal hemoglobin synthesis'20056,930,172'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20056,899,882'Endothelial cell growth factor methods of isolation and expression'20056,897,294'Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production'20056,750,044'Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids'20046,723,535'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20046,664,376'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20036,653,287'Use of leukemia inhibitory factor and endothelin antagonists'20036,635,468'Secreted and transmembrane polypeptides and nucleic acids encoding the same'20036,620,784'Uses of VEGF-E'20036,551,822'NL4 tie ligand homologue'20036,455,283'Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)'20026,413,770'NL4 tie ligand homologue nucleic acid'20026,391,311'Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1'20026,383,486'Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production'20026,348,351'Tie receptor tyrosine kinase ligand homologues'20026,156,733'Use of leukemia inhibitory factor and endothelin antagonists'20006,133,231'Angiogenesis using hepatocyte growth factor'20006,100,071'Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production'20006,074,873'Nucleic acids encoding NL-3'20006,057,428'Variants of vascular endothelial cell growth factor'20006,020,473'Nucleic acids encoding variants of vascular endothelial cell growth factor'20005,952,199'Chimeric receptors as inhibitors of vascular endothelial growth factor activity, and processes for their production'19995,837,241'Method of treating heart failure using leukemia inhibitory factor antagonists optionally with endothelin antagonists'19985,573,762'Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy'19965,332,671'Production of vascular endothelial cell growth factor and DNA encoding same'1994

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1994–2016Patents assigned to GENENTECH INC (99)· patent assignee history
1994–2005Based in Belvedere, CA, US· patent location history
1996–2016Based in San Francisco, CA, US· patent location history
2012–2016Patents assigned to FERRARA NAPOLEONE (12)· patent assignee history
2012–2016Patents assigned to CHEN HELEN HSIFEI (4)· patent assignee history
2012–2016Patents assigned to DAVIS-SMYTH TERRI LYNN (4)· patent assignee history
2012–2016Patents assigned to PRESTA LEONARD (4)· patent assignee history
2014Based in South San Francisco, CA, US· patent location history
2016Based in La Jolla, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
GENENTECH INC991994–2016
FERRARA NAPOLEONEself122012–2016
CHEN HELEN HSIFEI42012–2016
DAVIS-SMYTH TERRI LYNN42012–2016
PRESTA LEONARD42012–2016
Locations
LocationPatentsSpan
San Francisco, California, US961996–2016
Belvedere, California, US21994–2005
La Jolla, California, US12016
South San Francisco, California, US12014